Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas
Life Science Alliance · 2025-12 · 8 (12) · e202503359
DOI: 10.26508/lsa.202503359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 24.09.2025. Verfasst von Niousha Ahmari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinna…. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, DOD, Revolution Medicines.
Abstract (Originalsprache)
Loss of NF1 in Schwann cells leads to activation of the RAS-MAPK pathway, followed by immune cell recruitment and development of benign nerve tumors (PNFs). MEK inhibitors, which shrink most PNFs, also reduce tumor-associated myeloid cells. We tested whether SHP2 inhibition, predicted to block RAS-MAPK signaling and exert immunomodulatory effects, alters tumor volume or the immune microenvironment in PNFs, using flow cytometry and single-cell RNA sequencing. We found that both cobimetinib and daytime RMC-4550 similarly reduced tumor volume. The abundance of CD163-negative PNF-associated macrophages, derived from circulating monocytes, correlated with tumor size. Combining SHP2 inhibition with anti-PD1 altered tumor monocyte phenotype and reversed SHP2-mediated tumor shrinkage. Diurnal patterns of monocyte trafficking were disrupted in tumor-bearing mice, and SHP2 inhibition reduced tumor volume only when administered during the day, when myeloid infiltration was low. These findings suggest that SHP2 inhibitor–driven tumor shrinkage requires targeting monocyte-derived macrophages and is influenced by the timing of drug administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Divisions of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
- Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
- Divisions of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA nancy.ratner@cchmc.org.
ORCID-Profile: Jianqiang Wu, Tilat A Rizvi, Leah J Kershner, Mi-Ok Kim, Eva Dombi, Jack Shern, Nancy Ratner
Förderung
- NINDS NIH HHS
- DOD
- Revolution Medicines
Zitieren
APA
Ahmari, N., Choi, K., Wu, J., Rizvi, T. A., Jackson, M., Kershner, L. J., Kim, M. O., Zhang, X., Dombi, E., Shern, J., Hildeman, D. A., & Ratner, N. (2025). Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Science Alliance, 8(12), e202503359. https://doi.org/10.26508/lsa.202503359
Vancouver
Ahmari N, Choi K, Wu J, Rizvi TA, Jackson M, Kershner LJ, et al. Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Science Alliance. 2025;8(12):e202503359. doi:10.26508/lsa.202503359
BibTeX
@article{Ahmari2025,
author = {Ahmari, Niousha and Choi, Kwangmin and Wu, Jianqiang and Rizvi, Tilat A and Jackson, Mark and Kershner, Leah J and Kim, Mi-Ok and Zhang, Xiyuan and Dombi, Eva and Shern, Jack and Hildeman, David A and Ratner, Nancy},
title = {Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas},
journal = {Life Science Alliance},
year = {2025},
volume = {8},
number = {12},
pages = {e202503359},
doi = {10.26508/lsa.202503359}
}
EUVIMED